Karen Bedirian: Happy to share that IMMONC received regulatory approval to conduct a trial of BAL+BOT among patients with metastatic non-small cell lung cancer

Karen Bedirian, Projects Director at Immune Oncology Research Institute, shared on LinkedIn:

“Happy to share that IMMONC received regulatory approval to conduct a clinical trial of BAL+BOT among patients with metastatic non-small cell lung cancer.
We received the approval of the Center of Drug and Medical Technology in just 30 working days and the approval of the MoH Ethics Committee in just 9 working days.

Grateful for the team’s efforts. Immune Oncology Research Institute
Thank you Agenus for the continued support.”

Source: Karen Bedirian/LinkedIn